Summary of Adverse Events
death, Discontinuations
ADVERSE EVENTS
The percentages of participants with AEs were 43.1% in the placebo group and 65.5% in the gefapixant 45 mg BID group. The most common AEs were related to taste and were more commonly reported by participants on gefapixant. The overall incidence of serious AEs was < 2% and similar between placebo and gefapixant. There was one death, which occurred in the placebo group. Discontinuations due to AEs were higher in the gefapixant 45 mg BID group (Table Summary of adverse events